EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

Andrea Fava iD, Michelle Petri iD, Patrick G Gavin, Eszter Csomor, Philip Z Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.70089 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Andrea Fava und 8 weiteren Autor:innen. Beteiligte Einrichtung: Divison of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Hauptthemen laut MEDLINE: Lupus Nephritis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier NCT02547922). We studied the impact of anifrolumab treatment on urinary biomarker expression in patients with LN through proteomic analysis of samples from TULIP‐LN.

Methods

Urine samples were collected at weeks 0, 12, and 48 from patients treated with the anifrolumab basic regimen (n = 35), intensified regimen (n = 42), or placebo (n = 35), in addition to standard therapy, and analyzed for the presence of 197 proteins. The impact of anifrolumab relative to placebo on prespecified biomarkers linked to histologic activity was assessed, and a comparison of responders versus nonresponders was conducted on proteins detected in ≥75% of samples.

Results

Anifrolumab treatment significantly reduced urinary CD163 and monocyte chemoattractant protein 1 expression at week 12 versus placebo, including in patients classified as proteinuric nonresponders across all regimens. By week 48, biomarker levels declined in all groups, indicating that standard therapy alone can eventually suppress intrarenal inflammation but with slower kinetics. Proteomic analyses further revealed that anifrolumab was superior to placebo in reducing the proteomic inflammatory signature, regardless of responder status.

Conclusion

Compared with placebo, anifrolumab treatment significantly reduced urinary biomarkers of renal histologic activity in patients with LN, which may accelerate the resolution of intrarenal inflammation, potentially preventing damage accrual. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisAntibodies, Monoclonal, HumanizedHumansBiomarkersFemaleAdultMaleProteomicsAntigens, CDChemokine CCL2Antigens, Differentiation, MyelomonocyticInflammationCD163 AntigenReceptors, Cell SurfaceDouble-Blind MethodTreatment OutcomeMiddle AgedKidney

Substanzen

BiomarkersAntibodies, Monoclonal, HumanizedanifrolumabAntigens, CDChemokine CCL2Antigens, Differentiation, MyelomonocyticCD163 AntigenReceptors, Cell SurfaceCCL2 protein, human

Autor:innen und Institutionen

  • Divison of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Translational Science and Experimental Medicine, Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
  • Translational Science and Experimental Medicine, Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Translational Science and Experimental Medicine, Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Andrea Fava, Michelle Petri

Förderung

  • AstraZeneca

Zitieren

APA

Fava, A., Petri, M., Gavin, P. G., Csomor, E., Brohawn, P. Z., Muthas, D., Platt, A., Lindholm, C., & Ferrari, N. (2026). Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial. Arthritis & Rheumatology. https://doi.org/10.1002/art.70089

Vancouver

Fava A, Petri M, Gavin PG, Csomor E, Brohawn PZ, Muthas D, et al. Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial. Arthritis & Rheumatology. 2026. doi:10.1002/art.70089

BibTeX
@article{Fava2026,
  author = {Fava, Andrea and Petri, Michelle and Gavin, Patrick G and Csomor, Eszter and Brohawn, Philip Z and Muthas, Daniel and Platt, Adam and Lindholm, Catharina and Ferrari, Nicola},
  title = {Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70089}
}
Kostenlos starten →